CY1108179T1 - Τροποποιημενος παραγοντας viii - Google Patents

Τροποποιημενος παραγοντας viii

Info

Publication number
CY1108179T1
CY1108179T1 CY20081100709T CY081100709T CY1108179T1 CY 1108179 T1 CY1108179 T1 CY 1108179T1 CY 20081100709 T CY20081100709 T CY 20081100709T CY 081100709 T CY081100709 T CY 081100709T CY 1108179 T1 CY1108179 T1 CY 1108179T1
Authority
CY
Cyprus
Prior art keywords
factor viii
modified factor
modified
hemophilia
treatment
Prior art date
Application number
CY20081100709T
Other languages
Greek (el)
English (en)
Inventor
John S Lollar
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of CY1108179T1 publication Critical patent/CY1108179T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Glass Compositions (AREA)
  • Fish Paste Products (AREA)
  • Steroid Compounds (AREA)
CY20081100709T 2000-03-10 2008-07-07 Τροποποιημενος παραγοντας viii CY1108179T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/523,656 US6458563B1 (en) 1996-06-26 2000-03-10 Modified factor VIII
EP01910853A EP1280540B1 (en) 2000-03-10 2001-02-16 Modified factor viii

Publications (1)

Publication Number Publication Date
CY1108179T1 true CY1108179T1 (el) 2014-02-12

Family

ID=24085870

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20081100709T CY1108179T1 (el) 2000-03-10 2008-07-07 Τροποποιημενος παραγοντας viii
CY2016011C CY2016011I2 (el) 2000-03-10 2016-05-10 Τροποποιημενος παραγοντας viii

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2016011C CY2016011I2 (el) 2000-03-10 2016-05-10 Τροποποιημενος παραγοντας viii

Country Status (35)

Country Link
US (3) US6458563B1 (https=)
EP (1) EP1280540B1 (https=)
JP (1) JP4044337B2 (https=)
KR (1) KR100485525B1 (https=)
CN (1) CN1191360C (https=)
AT (1) ATE391512T1 (https=)
AU (2) AU3841601A (https=)
BE (1) BE2016C024I2 (https=)
BR (2) BRPI0109131B8 (https=)
CA (1) CA2400295C (https=)
CY (2) CY1108179T1 (https=)
CZ (1) CZ298250B6 (https=)
DE (1) DE60133541T2 (https=)
DK (1) DK1280540T3 (https=)
EE (1) EE05075B1 (https=)
ES (1) ES2304379T3 (https=)
FR (1) FR16C0016I2 (https=)
HU (2) HU227804B1 (https=)
IL (2) IL151371A0 (https=)
LT (1) LTC1280540I2 (https=)
LU (1) LU93049I2 (https=)
ME (1) MEP8209A (https=)
MX (1) MXPA02008798A (https=)
NL (1) NL300808I2 (https=)
NO (2) NO331935B1 (https=)
NZ (1) NZ520799A (https=)
PL (1) PL202936B1 (https=)
PT (1) PT1280540E (https=)
RS (1) RS50364B (https=)
RU (1) RU2285724C2 (https=)
SI (1) SI1280540T1 (https=)
SK (1) SK286205B6 (https=)
UA (1) UA75064C2 (https=)
WO (1) WO2001068109A1 (https=)
ZA (1) ZA200206810B (https=)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
JP2005518181A (ja) * 2001-01-12 2005-06-23 ジ・アメリカン・ナショナル・レッド・クロス 第ｖｉｉｉ因子のヘパラン硫酸プロテオグリカン仲介性クリアランスを低下させるための方法および組成物
ES2319745T3 (es) * 2001-10-05 2009-05-12 Expression Therapeutics, Llc Secuencias de acidos nucleicos y aminoacidos que codifican polipeptidos de factor viii de alto nivel de expresion, y metodos de uso.
US20040249134A1 (en) * 2001-11-30 2004-12-09 Lollar John S. Factor viii c2 domain variants
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
PT1636261E (pt) * 2003-06-26 2007-11-08 Merck Patent Gmbh Proteínas trombopoietina com propriedades melhoradas
US20050059023A1 (en) * 2003-09-16 2005-03-17 Cantor Thomas L. Methods and kits for monitoring resistance to therapeutic agents
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
CA2547569C (en) * 2003-12-03 2013-04-16 University Of Rochester Recombinant factor viii having increased specific activity
DK1750733T3 (da) * 2004-05-03 2014-01-20 Univ Emory FREMGANGSMÅDE TIL INDGIVELSE AF SVINE-B-DOMÆNELØS fVIII
WO2005123928A1 (en) * 2004-06-08 2005-12-29 Battelle Memorial Institute Production of human coagulation factor viii from plant cells and whole plants
PT2363414T (pt) * 2004-11-12 2022-08-04 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
US20100256062A1 (en) 2004-12-06 2010-10-07 Howard Tommy E Allelic Variants of Human Factor VIII
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090215025A1 (en) 2005-12-07 2009-08-27 Technische Universitat Munchen Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
DE602007007923D1 (de) * 2006-04-11 2010-09-02 Csl Behring Gmbh Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
CA2673459C (en) * 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
EP1935430A1 (en) * 2006-12-22 2008-06-25 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
EP1988101A1 (en) * 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
CN101965409A (zh) * 2007-11-01 2011-02-02 罗切斯特大学 具有增加的稳定性的重组因子viii
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
NO2440239T3 (https=) 2009-06-09 2018-02-10
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
EP2498803A4 (en) * 2009-11-13 2013-05-15 Puget Sound Blood Ct FACTOR VIII CELL EPITOPARIANTS WITH REDUCED IMMUNOGENITY
SI2506868T1 (en) 2009-12-06 2018-04-30 Bioverativ Therapeutics Inc. HYPER AND HYBRID POLYPETTIDES FACTOR VIII-FC AND METHODS FOR THEIR USE
EP2524054A2 (en) * 2010-01-14 2012-11-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
DK2635297T3 (da) 2010-11-05 2019-05-06 Baxalta GmbH En ny variant af antihæmofil faktor viii, der har en øget specifik aktivitet
BR112013017281A2 (pt) * 2011-01-05 2016-09-20 Expression Therapeutics Llc método e sistema para cultura de células em suspensão
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
PT3513804T (pt) 2011-07-08 2022-06-02 Bioverativ Therapeutics Inc Polipéptidos fator viii híbridos e quiméricos, e métodos de utilização dos mesmos
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
CN102277379B (zh) * 2011-08-18 2013-07-24 中国科学院遗传与发育生物学研究所 表达凝血因子viii的表达载体及其应用
CN104271150A (zh) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
EA038705B1 (ru) 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
CA2875247A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
WO2013185113A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
CN104661674A (zh) 2012-07-11 2015-05-27 阿穆尼克斯运营公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
HK1213767A1 (zh) 2012-10-18 2016-07-15 Bioverativ Therapeutics Inc. 使用固定劑量凝血因子的方法
HK1214539A1 (zh) 2012-10-30 2016-07-29 Bioverativ Therapeutics Inc. 應用viii因子多肽的方法
EP2928303A4 (en) 2012-12-07 2016-07-13 Haplomics Inc FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION
WO2014127215A1 (en) 2013-02-15 2014-08-21 Biogen Idec Ma Inc. Optimized factor viii gene
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
EP4122487A1 (en) 2013-03-15 2023-01-25 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
CN113817069A (zh) 2013-06-28 2021-12-21 比奥贝拉蒂治疗公司 具有xten的凝血酶可裂解连接子和其用途
WO2015021423A2 (en) 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification of chimeric fviii molecules
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
WO2015059121A1 (en) 2013-10-22 2015-04-30 Dbv Technologies Method of treating haemophilia by inducing tolerance to blood factors
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
WO2015120056A1 (en) 2014-02-04 2015-08-13 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
CA2940127A1 (en) * 2014-02-19 2015-08-27 Bloodworks Factor viii b cell epitope variants having reduced immunogenicity
WO2015132724A1 (en) 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
EA202190827A1 (ru) 2015-11-13 2021-11-30 Баксалта Инкорпорейтед Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
CA3005565A1 (en) 2015-11-13 2017-05-18 Baxalta Incorporated Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
CA3012695A1 (en) 2016-02-01 2017-08-10 Bioverativ Therapeutics Inc. Optimized factor viii genes
WO2017222337A1 (ko) 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
JP2019536794A (ja) 2016-12-02 2019-12-19 バイオベラティブ セラピューティクス インコーポレイテッド 凝固因子に対する免疫寛容を誘導する方法
JP2020519272A (ja) * 2017-05-09 2020-07-02 エモリー ユニバーシティー 凝固因子変異体及びその使用
NZ762100A (en) 2017-08-09 2025-12-19 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
AU2019215063B2 (en) 2018-02-01 2025-10-16 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing Factor VIII
BR112020020084A2 (pt) 2018-04-04 2021-01-05 Sigilon Therapeutics, Inc. Partícula, preparação de uma pluralidade de partículas, método de preparação de uma partícula, e, composição de partículas.
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a
US12091675B2 (en) 2018-07-16 2024-09-17 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression
EP3833766A1 (en) 2018-08-09 2021-06-16 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
CN114007637A (zh) 2019-06-19 2022-02-01 比奥维拉迪维治疗股份有限公司 用于治疗血友病和低骨矿物质密度的重组因子viii-fc
CN114375205A (zh) 2019-06-20 2022-04-19 武田药品工业株式会社 用基于病毒的基因疗法进行治疗的方法
KR20220097891A (ko) 2019-09-30 2022-07-08 바이오버라티브 테라퓨틱스 인크. 렌티바이러스 벡터 제형
WO2021119357A2 (en) 2019-12-12 2021-06-17 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
MX2023000156A (es) 2020-06-24 2023-02-16 Bioverativ Therapeutics Inc Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina.
TW202246505A (zh) * 2021-03-05 2022-12-01 俄羅斯聯邦商亞那拜恩有限公司 編碼凝血因子ｉｘ蛋白的密碼子優化的核酸及其用途
US11906532B2 (en) 2021-03-31 2024-02-20 Haemonetics Corporation Hemostasis measurement device quality control formulations
EP4355768A1 (en) 2021-06-14 2024-04-24 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
AU2022332276A1 (en) 2021-08-23 2024-04-04 Bioverativ Therapeutics Inc. Optimized factor viii genes
TW202346327A (zh) 2021-09-30 2023-12-01 美商百歐維拉提夫治療公司 編碼具有降低免疫原性的因子ｖｉｉｉ多肽之核酸
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2025008774A1 (en) 2023-07-05 2025-01-09 Takeda Pharmaceutical Company Limited Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
ES8801674A1 (es) 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
CA2351200A1 (en) * 1989-12-01 1991-06-13 Gene Pharming Europe Bv Production of recombinant polypeptides by bovine species and transgenic methods
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
WO1997003191A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
PL206105B1 (pl) * 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej
US20040249134A1 (en) * 2001-11-30 2004-12-09 Lollar John S. Factor viii c2 domain variants
US7105745B2 (en) * 2002-12-31 2006-09-12 Thomas & Betts International, Inc. Water resistant electrical floor box cover assembly

Also Published As

Publication number Publication date
EP1280540A4 (en) 2004-11-03
JP4044337B2 (ja) 2008-02-06
BRPI0109131B1 (pt) 2020-08-25
HUS1600020I1 (hu) 2016-06-28
LU93049I2 (fr) 2016-06-27
WO2001068109A1 (en) 2001-09-20
DE60133541T2 (de) 2009-05-07
NO2016007I2 (no) 2016-05-10
IL151371A (en) 2010-12-30
ME00601B (me) 2011-12-20
US7012132B2 (en) 2006-03-14
IL151371A0 (en) 2003-04-10
EP1280540A1 (en) 2003-02-05
SK286205B6 (sk) 2008-05-06
NO2016007I1 (no) 2016-05-10
BR122013026957A8 (pt) 2017-02-21
JP2003526358A (ja) 2003-09-09
CZ20023346A3 (cs) 2003-01-15
ES2304379T3 (es) 2008-10-16
BR0109131A (pt) 2004-12-07
ATE391512T1 (de) 2008-04-15
US20030068785A1 (en) 2003-04-10
CY2016011I1 (el) 2016-10-05
HU227804B1 (en) 2012-03-28
CA2400295A1 (en) 2001-09-20
FR16C0016I2 (fr) 2018-11-02
NO331935B1 (no) 2012-05-07
SK14392002A3 (sk) 2003-06-03
NO20024296L (no) 2002-11-08
KR20020081426A (ko) 2002-10-26
CN1416348A (zh) 2003-05-07
US20050079584A1 (en) 2005-04-14
ZA200206810B (en) 2003-11-26
AU3841601A (en) 2001-09-24
DK1280540T3 (da) 2008-07-14
BRPI0109131B8 (pt) 2021-07-06
MEP8209A (en) 2011-12-20
PT1280540E (pt) 2008-06-09
MXPA02008798A (es) 2003-04-25
CY2016011I2 (el) 2016-10-05
YU68002A (sh) 2005-11-28
BE2016C024I2 (https=) 2020-01-30
SI1280540T1 (sl) 2008-08-31
US7122634B2 (en) 2006-10-17
US6458563B1 (en) 2002-10-01
NL300808I1 (https=) 2016-05-18
AU2001238416B2 (en) 2004-09-02
HUP0300586A2 (hu) 2003-06-28
NZ520799A (en) 2004-06-25
NO20024296D0 (no) 2002-09-09
RU2285724C2 (ru) 2006-10-20
EE05075B1 (et) 2008-10-15
CN1191360C (zh) 2005-03-02
UA75064C2 (en) 2006-03-15
KR100485525B1 (ko) 2005-04-28
HK1051004A1 (en) 2003-07-18
PL202936B1 (pl) 2009-08-31
LTC1280540I2 (lt) 2020-05-25
NL300808I2 (nl) 2020-12-21
CZ298250B6 (cs) 2007-08-01
HUP0300586A3 (en) 2006-11-28
DE60133541D1 (de) 2008-05-21
RS50364B (sr) 2009-11-10
FR16C0016I1 (https=) 2016-04-29
PL359672A1 (en) 2004-09-06
RU2002124123A (ru) 2004-03-27
EE200200510A (et) 2004-02-16
EP1280540B1 (en) 2008-04-09
BR122013026957A2 (https=) 2004-12-07
CA2400295C (en) 2012-01-10

Similar Documents

Publication Publication Date Title
CY1108179T1 (el) Τροποποιημενος παραγοντας viii
CY1108007T1 (el) Φαρμακευτικες συνθεσεις βοτουλινικης τοξινης
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
CY1122841T1 (el) Πολυαλκυλενικες πολυμερικες ενωσεις και χρησεις αυτων
ES2333598T5 (es) Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
CY1110462T1 (el) Θεραπεια της ηπατικης ινωσης με αντισωματα εναντιον της ενσωματινης (ιντεγκρινης) αλφα v βητα 6
BRPI0411321A (pt) vetor viral associado a adenovìrus, composição farmacêutica e método para tratar doença de alzheimer, e, uso do vetor viral associado a adenovìrus
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
CY2017009I1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
MXPA04003333A (es) Remodelado y glicoconjugacion de peptidos.
CY1112862T1 (el) Θραυσματα μονοσθενους αντισωματος χρησιμα ως θεραπευτικα
MXPA03007315A (es) Composiciones antitranspirantes o desodorantes.
DK1660650T3 (da) Forbedrede Sso7-polymerase-konjugat-proteiner
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
EE200300121A (et) CB1 retseptori antagonisti ja sibutramiini kombinatsioon, neid sisaldav farmatseutiline kompositsioon ja kasutamine lihavuse raviks
CY1112458T1 (el) Ενα αντισωμα ειδικο για διαλυτο baff για χρηση στην αντιμετωπιση του καρκινου
DK1326630T3 (da) Anvendelse af GLP-2-peptider
DK1487493T3 (da) Konjugater af cytotoksiske midler og biologisk aktive peptider
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
CY1108281T1 (el) 17-α-υποκατασταθεισα-11-β-υποκατασταθεισα-4-αρυλ και 21-υποκατασταθεισα 19-νορπρεγναδιενοδιονη ως νεοι αντι-προεμμηνορροϊκοι παραγοντες.
ATE330017T1 (de) Kallikrein gen
CY1112957T1 (el) Μη νευροτοξικοι παραγοντες, οι οποιοι ενεργοποιουν το πλασμινογονο για τη θεραπευτικη αγωγη εγκεφαλικου επεισοδιου
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
ATE359279T1 (de) Moschus-geruchsstoffe